My Quote Request
No products added yet
6505-01-480-4799
20 Products
TNKASE
TENECTEPLASE FOR IN
NSN, MFG P/N
6505014804799
NSN
6505-01-480-4799
MFG
GENENTECH INC.
Description
GENERAL CHARACTERISTICS ITEM DESCRIPTION: STORE AT CONTROLLED ROOM TEMPERATURE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: TENECTEPLASE FOR INJECTION SINGLE-BOLUS TISSUE PLASMINOGEN
SPECIAL FEATURES: SINGLE-BOLUS TISSUE PLASMINOGEN ACTIVATOR THROMBOLYTIC AGENT AGENT 50MG VIAL WITH ONE 10ML VIAL OF STERILE WATER FOR INJECTION;ONE B-D 10CC SYRINGE WITH TWINPAK DUAL CANNULA DEVICE,AND THREE ALCOHOL SCRUB PADS;TNKASE NOMINALLY CONTAINS 52.5MG
~1: TENECTEPLASE;0.55G L-ARGININE;0.17G PHOSPHORIC ACID;4.3MG POLYSORBATE 20
Related Searches:
00-0751
MUPIROCIN OINTMENT
NSN, MFG P/N
6505014805678
NSN
6505-01-480-5678
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
ACTIVE INGREDIENT AND STRENGTH: 20.000 MUPIROCIN MILLIGRAMS
ADMINISTRATION: TOPICAL
III PART NAME ASSIGNED BY CONTROLLING AGENCY: MUPIROCIN OINTMENT 20MG TOPICAL 22GM TUBE
III SUPPLEMENTARY FEATURES: EACH GRAM OF BACTROBAN OINTMENT 2% CONTAINS 20 MG MUPIROCIN IN A BLAND WATER MISCIBLE OINTMENT BASE; NOT FOR OPHTHALMIC USE
MEDICAMENT BASE TYPE: OINTMENT BASE
PRIMARY CONTAINER CONTENT QUANTITY: 22.000 GRAMS
PRIMARY CONTAINER TYPE: TUBE
SPECIAL FEATURES: FOR TX OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS AND STREPTOCOCCUS PYOGENES; STORE AT CONTROLLED ROOM TEMP 20 TO 25 DEG C
USAGE DESIGN: FOR DERMATOLOGIC USE
Related Searches:
BACTROBAN
MUPIROCIN OINTMENT
NSN, MFG P/N
6505014805678
NSN
6505-01-480-5678
MFG
GLAXOSMITHKLINE HOLDINGS AMERICAS INC. DIV SMITHKLINE BEECHAM CORPORATION
Description
ACTIVE INGREDIENT AND STRENGTH: 20.000 MUPIROCIN MILLIGRAMS
ADMINISTRATION: TOPICAL
III PART NAME ASSIGNED BY CONTROLLING AGENCY: MUPIROCIN OINTMENT 20MG TOPICAL 22GM TUBE
III SUPPLEMENTARY FEATURES: EACH GRAM OF BACTROBAN OINTMENT 2% CONTAINS 20 MG MUPIROCIN IN A BLAND WATER MISCIBLE OINTMENT BASE; NOT FOR OPHTHALMIC USE
MEDICAMENT BASE TYPE: OINTMENT BASE
PRIMARY CONTAINER CONTENT QUANTITY: 22.000 GRAMS
PRIMARY CONTAINER TYPE: TUBE
SPECIAL FEATURES: FOR TX OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS AND STREPTOCOCCUS PYOGENES; STORE AT CONTROLLED ROOM TEMP 20 TO 25 DEG C
USAGE DESIGN: FOR DERMATOLOGIC USE
Related Searches:
NDC00029-1525-44
MUPIROCIN OINTMENT
NSN, MFG P/N
6505014805678
NSN
6505-01-480-5678
MFG
GLAXOSMITHKLINE HOLDINGS AMERICAS INC. DIV SMITHKLINE BEECHAM CORPORATION
Description
ACTIVE INGREDIENT AND STRENGTH: 20.000 MUPIROCIN MILLIGRAMS
ADMINISTRATION: TOPICAL
III PART NAME ASSIGNED BY CONTROLLING AGENCY: MUPIROCIN OINTMENT 20MG TOPICAL 22GM TUBE
III SUPPLEMENTARY FEATURES: EACH GRAM OF BACTROBAN OINTMENT 2% CONTAINS 20 MG MUPIROCIN IN A BLAND WATER MISCIBLE OINTMENT BASE; NOT FOR OPHTHALMIC USE
MEDICAMENT BASE TYPE: OINTMENT BASE
PRIMARY CONTAINER CONTENT QUANTITY: 22.000 GRAMS
PRIMARY CONTAINER TYPE: TUBE
SPECIAL FEATURES: FOR TX OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS AND STREPTOCOCCUS PYOGENES; STORE AT CONTROLLED ROOM TEMP 20 TO 25 DEG C
USAGE DESIGN: FOR DERMATOLOGIC USE
Related Searches:
NDC00093-1010-42
MUPIROCIN OINTMENT
NSN, MFG P/N
6505014805678
NSN
6505-01-480-5678
MFG
TEVA PHARMACEUTICALS USA INC. DBA GATE PHARMACEUTICALS
Description
ACTIVE INGREDIENT AND STRENGTH: 20.000 MUPIROCIN MILLIGRAMS
ADMINISTRATION: TOPICAL
III PART NAME ASSIGNED BY CONTROLLING AGENCY: MUPIROCIN OINTMENT 20MG TOPICAL 22GM TUBE
III SUPPLEMENTARY FEATURES: EACH GRAM OF BACTROBAN OINTMENT 2% CONTAINS 20 MG MUPIROCIN IN A BLAND WATER MISCIBLE OINTMENT BASE; NOT FOR OPHTHALMIC USE
MEDICAMENT BASE TYPE: OINTMENT BASE
PRIMARY CONTAINER CONTENT QUANTITY: 22.000 GRAMS
PRIMARY CONTAINER TYPE: TUBE
SPECIAL FEATURES: FOR TX OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS AND STREPTOCOCCUS PYOGENES; STORE AT CONTROLLED ROOM TEMP 20 TO 25 DEG C
USAGE DESIGN: FOR DERMATOLOGIC USE
Related Searches:
NDC51672-1312-00
MUPIROCIN OINTMENT
NSN, MFG P/N
6505014805678
NSN
6505-01-480-5678
MFG
TARO PHARMACEUTICALS INC
Description
ACTIVE INGREDIENT AND STRENGTH: 20.000 MUPIROCIN MILLIGRAMS
ADMINISTRATION: TOPICAL
III PART NAME ASSIGNED BY CONTROLLING AGENCY: MUPIROCIN OINTMENT 20MG TOPICAL 22GM TUBE
III SUPPLEMENTARY FEATURES: EACH GRAM OF BACTROBAN OINTMENT 2% CONTAINS 20 MG MUPIROCIN IN A BLAND WATER MISCIBLE OINTMENT BASE; NOT FOR OPHTHALMIC USE
MEDICAMENT BASE TYPE: OINTMENT BASE
PRIMARY CONTAINER CONTENT QUANTITY: 22.000 GRAMS
PRIMARY CONTAINER TYPE: TUBE
SPECIAL FEATURES: FOR TX OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS AND STREPTOCOCCUS PYOGENES; STORE AT CONTROLLED ROOM TEMP 20 TO 25 DEG C
USAGE DESIGN: FOR DERMATOLOGIC USE
Related Searches:
8065183975
VISCOAT OPTHALMIC
NSN, MFG P/N
6505014805927
NSN
6505-01-480-5927
MFG
ALCON LABORATORIES INC .
Description
SPECIAL FEATURES: VISCOELASTICS; VISCOAT OPTHALMIC DEVICE .75 ML; 4% CHONDROITIN SULFATE;3% SODIUM HYALURONATE
Related Searches:
105
BETAMETHASONE SODIUM PHOSPHATE AND GENTAMICIN SULFATE OPHTHALMIC-OTIC SOLUTION
NSN, MFG P/N
6505014806327
NSN
6505-01-480-6327
105
BETAMETHASONE SODIUM PHOSPHATE AND GENTAMICIN SULFATE OPHTHALMIC-OTIC SOLUTION
NSN, MFG P/N
6505014806327
NSN
6505-01-480-6327
MFG
ALLERGAN INC
Description
PRIMARY CONTAINER CONTENT QUANTITY: 5.000 MILLIGRAMS
PRIMARY CONTAINER TYPE: ANY ACCEPTABLE
SPECIAL FEATURES: GENTAMICIN EYEDROP
Related Searches:
GENOPTIC
BETAMETHASONE SODIUM PHOSPHATE AND GENTAMICIN SULFATE OPHTHALMIC-OTIC SOLUTION
NSN, MFG P/N
6505014806327
NSN
6505-01-480-6327
GENOPTIC
BETAMETHASONE SODIUM PHOSPHATE AND GENTAMICIN SULFATE OPHTHALMIC-OTIC SOLUTION
NSN, MFG P/N
6505014806327
NSN
6505-01-480-6327
MFG
ALLERGAN INC
Description
PRIMARY CONTAINER CONTENT QUANTITY: 5.000 MILLIGRAMS
PRIMARY CONTAINER TYPE: ANY ACCEPTABLE
SPECIAL FEATURES: GENTAMICIN EYEDROP
Related Searches:
00-0755
FUROSEMIDE INJECTION,USP
NSN, MFG P/N
6505014806901
NSN
6505-01-480-6901
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 10.000 MILLIGRAMS FUROSEMIDE PER MILLILITER
ADMINISTRATION: INTRAPERITONEAL OR INTRAVENOUS
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: FUROSEMIDE INJECTION USP 10MG/ML STERILE 10ML SYRINGE 10'S
III SUPPLEMENTARY FEATURES: ANSYR PLASTIC SYRINGE MOLDED FROM SPECIALLY FORMULATED POLYPROPYLENE
PHARMACEUTICAL VEHICLE TYPE: AQUEOUS
PRIMARY CONTAINER CONTENT QUANTITY: 10.000 MILLILITERS
PRIMARY CONTAINER TYPE: SYRINGE
SPECIAL FEATURES: CONTAINS NO PRESERVATIVES; STORE AT CONTROLLED ROOM TEMP 15 TO 30 DEG C; PROTECT FROM LIGHT; FOR TX OF EDEMA ASSOCIATED WITH CONGESTIVE HEART FAILURE, CIRRHOSIS OF THE LIVER AND RENAL DISEASE, INCLUDING NEPHROTIC SYNDROME
TOTAL PRIMARY CONTAINER QUANTITY: 10
Related Searches:
LASIX
FUROSEMIDE INJECTION,USP
NSN, MFG P/N
6505014806901
NSN
6505-01-480-6901
MFG
HOSPIRA INC.
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 10.000 MILLIGRAMS FUROSEMIDE PER MILLILITER
ADMINISTRATION: INTRAPERITONEAL OR INTRAVENOUS
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: FUROSEMIDE INJECTION USP 10MG/ML STERILE 10ML SYRINGE 10'S
III SUPPLEMENTARY FEATURES: ANSYR PLASTIC SYRINGE MOLDED FROM SPECIALLY FORMULATED POLYPROPYLENE
PHARMACEUTICAL VEHICLE TYPE: AQUEOUS
PRIMARY CONTAINER CONTENT QUANTITY: 10.000 MILLILITERS
PRIMARY CONTAINER TYPE: SYRINGE
SPECIAL FEATURES: CONTAINS NO PRESERVATIVES; STORE AT CONTROLLED ROOM TEMP 15 TO 30 DEG C; PROTECT FROM LIGHT; FOR TX OF EDEMA ASSOCIATED WITH CONGESTIVE HEART FAILURE, CIRRHOSIS OF THE LIVER AND RENAL DISEASE, INCLUDING NEPHROTIC SYNDROME
TOTAL PRIMARY CONTAINER QUANTITY: 10
Related Searches:
NDC00409-1639-10
FUROSEMIDE INJECTION,USP
NSN, MFG P/N
6505014806901
NSN
6505-01-480-6901
NDC00409-1639-10
FUROSEMIDE INJECTION,USP
NSN, MFG P/N
6505014806901
NSN
6505-01-480-6901
MFG
HOSPIRA INC.
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 10.000 MILLIGRAMS FUROSEMIDE PER MILLILITER
ADMINISTRATION: INTRAPERITONEAL OR INTRAVENOUS
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: FUROSEMIDE INJECTION USP 10MG/ML STERILE 10ML SYRINGE 10'S
III SUPPLEMENTARY FEATURES: ANSYR PLASTIC SYRINGE MOLDED FROM SPECIALLY FORMULATED POLYPROPYLENE
PHARMACEUTICAL VEHICLE TYPE: AQUEOUS
PRIMARY CONTAINER CONTENT QUANTITY: 10.000 MILLILITERS
PRIMARY CONTAINER TYPE: SYRINGE
SPECIAL FEATURES: CONTAINS NO PRESERVATIVES; STORE AT CONTROLLED ROOM TEMP 15 TO 30 DEG C; PROTECT FROM LIGHT; FOR TX OF EDEMA ASSOCIATED WITH CONGESTIVE HEART FAILURE, CIRRHOSIS OF THE LIVER AND RENAL DISEASE, INCLUDING NEPHROTIC SYNDROME
TOTAL PRIMARY CONTAINER QUANTITY: 10
Related Searches:
00-0758
TOLNAFTATE POWDER,USP
NSN, MFG P/N
6505014807897
NSN
6505-01-480-7897
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 1.000 PERCENTAGE, W/W TOLNAFTATE ACTIVE INGREDIENT
III PART NAME ASSIGNED BY CONTROLLING AGENCY: TOLNAFTATE POWDER USP ATHLETE FOOT JOCK ITCH RINGWORM 45GM
PHYSICAL FORM: POWDER
PRIMARY CONTAINER CONTENT QUANTITY: 45.000 GRAMS
PRIMARY CONTAINER TYPE: BOTTLE
SPECIAL FEATURES: FOR TX OF ATHLETE'S FOOT, JOCK ITCH AND RINGWORM; STORE BETWEEN 2 DEG AND 30 DEG C
Related Searches:
NDC45802-0034-86
TOLNAFTATE POWDER,USP
NSN, MFG P/N
6505014807897
NSN
6505-01-480-7897
NDC45802-0034-86
TOLNAFTATE POWDER,USP
NSN, MFG P/N
6505014807897
NSN
6505-01-480-7897
MFG
CLAY-PARK LABORATORIES INC
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 1.000 PERCENTAGE, W/W TOLNAFTATE ACTIVE INGREDIENT
III PART NAME ASSIGNED BY CONTROLLING AGENCY: TOLNAFTATE POWDER USP ATHLETE FOOT JOCK ITCH RINGWORM 45GM
PHYSICAL FORM: POWDER
PRIMARY CONTAINER CONTENT QUANTITY: 45.000 GRAMS
PRIMARY CONTAINER TYPE: BOTTLE
SPECIAL FEATURES: FOR TX OF ATHLETE'S FOOT, JOCK ITCH AND RINGWORM; STORE BETWEEN 2 DEG AND 30 DEG C
Related Searches:
ASSURE
SODIUM FLUORIDE TREATMENT KIT
NSN, MFG P/N
6505014811518
NSN
6505-01-481-1518
MFG
RELIANCE ORTHODONTIC PRODUCTS
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: ASSURE
SPECIAL FEATURES: CONTENTS OF KIT; ECONOMY KIT: 20 GM. PASTE; (1) 6 CC SEALANT; 9 GM. ETCHING AGENT; DISPOSABLE BRUSHES, SPATULAS AND MIXING PAD
Related Searches:
00-0757
NICOTINE POLACRILEX GUM,USP
NSN, MFG P/N
6505014813146
NSN
6505-01-481-3146
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: NICOTINE POLACRILEX CHEWING GUM 2MG STARTER KIT 110 PIECES
PRIMARY CONTAINER TYPE: PACKAGE
SPECIAL FEATURES: 2 MG STARTER KIT CONTAINS 110 PIECES
Related Searches:
NDC00536-3106-23
NICOTINE POLACRILEX GUM,USP
NSN, MFG P/N
6505014813146
NSN
6505-01-481-3146
NDC00536-3106-23
NICOTINE POLACRILEX GUM,USP
NSN, MFG P/N
6505014813146
NSN
6505-01-481-3146
MFG
WATSON PHARMACEUTICALS INC.
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: NICOTINE POLACRILEX CHEWING GUM 2MG STARTER KIT 110 PIECES
PRIMARY CONTAINER TYPE: PACKAGE
SPECIAL FEATURES: 2 MG STARTER KIT CONTAINS 110 PIECES
Related Searches:
NDC00766-7845-08
NICOTINE POLACRILEX GUM,USP
NSN, MFG P/N
6505014813146
NSN
6505-01-481-3146
NDC00766-7845-08
NICOTINE POLACRILEX GUM,USP
NSN, MFG P/N
6505014813146
NSN
6505-01-481-3146
MFG
GLAXO WELLCOME INC
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: NICOTINE POLACRILEX CHEWING GUM 2MG STARTER KIT 110 PIECES
PRIMARY CONTAINER TYPE: PACKAGE
SPECIAL FEATURES: 2 MG STARTER KIT CONTAINS 110 PIECES
Related Searches:
66550-1000IU
ANTIHEMOPHILIC FACTOR,USP
NSN, MFG P/N
6505014813797
NSN
6505-01-481-3797
66550-1000IU
ANTIHEMOPHILIC FACTOR,USP
NSN, MFG P/N
6505014813797
NSN
6505-01-481-3797
MFG
TALECRIS BIOTHERAPEUTICS INC.
Description
ADMINISTRATION: INTRAVENOUS
FEATURES PROVIDED: STERILE AND UNIT DOSE
PRIMARY CONTAINER CONTENT QUANTITY: 1000.000 INTERNATIONAL UNITS OF ACTIVE INGREDIENT
PRIMARY CONTAINER TYPE: BOTTLE, UNIT DOSE
SPECIAL FEATURES: DERIVED FROM HUMAN PLASMA
Related Searches:
KOATE-DVI
ANTIHEMOPHILIC FACTOR,USP
NSN, MFG P/N
6505014813797
NSN
6505-01-481-3797
MFG
TALECRIS BIOTHERAPEUTICS INC.
Description
ADMINISTRATION: INTRAVENOUS
FEATURES PROVIDED: STERILE AND UNIT DOSE
PRIMARY CONTAINER CONTENT QUANTITY: 1000.000 INTERNATIONAL UNITS OF ACTIVE INGREDIENT
PRIMARY CONTAINER TYPE: BOTTLE, UNIT DOSE
SPECIAL FEATURES: DERIVED FROM HUMAN PLASMA
